Evidence map›Paper›PMID 40400713›Full record

ArticleFrontiers in pharmacology2025

20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-X

Meng Xu, Feng Hao, Shuangshuang Wu, Zhanning Qu, Junying Li, Shuang Chen, Fang Fang, Yundong Zhao, Cheng Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meng Xu *College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, China.
Feng Hao *College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, China.
Shuangshuang WuDepartment of Pediatric Hematology, Children's Medical Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhanning QuCollege of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, China.
Junying LiSchool of Medical Technology, Beihua University, Jilin City, Jilin, China.
Shuang ChenCollege of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, China.
Fang FangSecond Affiliated Hospital of Guangdong Medical University, Guangzhou, Guangdong, China.
Yundong ZhaoSchool of Medical Technology, Beihua University, Jilin City, Jilin, China.
Cheng HuCollege of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, intensive chemotherapy with cytarabine and anthracycline (the "7 + 3" regimen) and hypomethylating agents remains the standard treatment for patients with acute myeloid leukemia (AML). Despite advances in treatment such as targeted therapies, patient outcomes remain unsatisfactory due to adverse drug reactions, susceptibility to drug resistance, and high recurrence rates. Consequently, there is an urgent need to develop safer and more efficacious treatments for AML. In this study, we examined the effects of 20(S)-protopanaxadiol (20(S)-PPD) on AML cells. Our findings indicate that 20(S)-PPD inhibits cell proliferation and induces apoptosis in AML cells. Mechanistically, 20(S)-PPD-induced apoptosis was at least partially dependent on the anti-apoptotic proteins MCL-1 and Bcl-X

Indexed as

20(S)-protopanaxadiolacute myeloid leukemiaapoptosisBcl-XLMCL-1

Identifiers

PMID40400713
PMCPMC12093104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.